TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05552131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T-wave coronary lithotripsy catheter system
Description: Subjects who plan to receive possible interventional therapy meet all admission criteria and do not meet any exclusion criteria, and enter the screening stage of this clinical trial after signing informed consent. All subjects who sign the informed consent will be provided with a unique subject screening number. All subjects who met the inclusion criteria and did not meet the exclusion criteria were enrolled and lumen pretreated with a coronary shock catheter system followed by the implantation of drug-eluting stents.
Study: NCT05146765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: Device: Use of mobile application Participants will be instructed to use the speech therapy app for 30 minutes to one hour per day over a 4-week period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: The patients will follow the treatment as usual, including conventional stroke therapy if needed based on the medical guidelines.
Study: NCT04841174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal massage
Description: The effect on gastric problems by applying abdominal massage to eligible participants in the study will be examined.
Study: NCT05549323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07054894
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05551156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal-assisted interaction
Description: Visits will occur on 3 consecutive days during your participant's inpatient hospital stay. A dog-handler team or a handler alone will visit participants with a dog for approximately 20 minutes at a convenient time for the participant. During this visit, the participant will be able to pet the dog if they wish. The handler will talk with the participants about the dog, the weather, sports, or other light topics. Participants can also suggest light topics to talk about as well.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conversational interaction
Description: Visits will occur on 3 consecutive days during your participant's inpatient hospital stay. A dog-handler team or a handler alone will visit participants without a dog for approximately 20 minutes at a convenient time for the participant. During this visit, the handler will talk with the participants about the weather, sports, or other light topics. Participants can also suggest light topics to talk about as well.
Study: NCT05403073

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided Suprainguinal Iliac Fascia Nerve Block.
Description: Pain management at ER Department will be as usually with iv drugs and ultrasound guided Suprainguinal Iliac Fascia Nerve Block.
Study: NCT05331937

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: rTMS (real versus sham) is used as adjuvant to ERP

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: rTMS (real versus sham) is used as adjuvant to ERP
Study: NCT05786300

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES+
Description: The Treatment Group will follow the rehabilitation protocol with the addition of the NMES+.~1st/2nd Week at 35 Hertz. 3rd/4th Week 50 Hertz. 5th/6th Week 70 Hertz.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rehab
Description: The Control Group will follow a protocol based on the latest available guidelines for the rehabilitation of the hamstrings lesions.~A weight-bearing protocol with a week by week progression on load, repetitions and sets.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehab
Description: The Control Group will follow a protocol based on the latest available guidelines for the rehabilitation of the hamstrings lesions.~A weight-bearing protocol with a week by week progression on load, repetitions and sets.
Study: NCT05332795

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: gouty patients, will receive metformin tablets (1000 mg) once daily for about 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: gouty patients, will receive placebo tablets once daily for about 3 months.
Study: NCT04832308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Description: This is a health coach driven exercise prescription for patients recommending 30 minutes or more of moderate effort walking 3-5 days a week with expected walk-rest-walk-rest intervals.
Study: NCT04320875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Anode electrode -C3/C4 (International 10-20 electroencephalogram system), contralateral side of the most affected knee) Cathode electrode- contralateral supraorbital area. 2 mA intensity for 20 minutes, one session/day for 3 days/week for 8 weeks)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: 1. Warm-up exercises: Walking at the usual speed on a flat surface for 10 min ( 3sets X10 Reps X 3 min rest in between)~2. Hamstring and calf gentle stretches. ( 3sets X10 Reps X 3 min rest in between)~3. Straight leg raise (SLR) ( 3sets X10 Reps X 3 min rest in between)~4. Quadriceps setting ( 3sets X10 Reps X 3 min rest in between)~5. Pillow squeeze ( 3sets X10 Reps X 3 min rest in between)~6. Heel raise ( 3sets X10 Reps X 3 min rest in between)~7. One leg balance ( 3sets X10 Reps X 3 min rest in between)~8. Step ups ( 3sets X10 Reps X 3 min rest in between)~9. Quadriceps strengthening exercises ( 3sets X10 Reps X 3 min rest in between)
Study: NCT05720247

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fibroscan
Description: Fibroscan is a safe and effective test using ultrasound to measure liver elasticity and can detect early signs of liver disease even before a patient shows symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: Short counselling session to discuss drinking behavior, risks to health and available sources of treatment and support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Intervention
Description: Short counselling session to discuss drinking behavior, risks to health and available sources of treatment and support.
Study: NCT05079087

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group blockade
Description: The PENG-block will be administered under ultrasound (US) guidance with a low frequency curvilinear probe. The probe will be placed parallel to the inguinal crease at the level of the anterior superior iliac spine. Scanning will be done with gradual caudal movement of the probe. After the anterior inferior iliac spine (AIIS) is visible, the probe will be turned slightly medial until the hyperechoic continuous shadow of the superior pubic ramus is visible. The Psoas muscle with its prominent tendon will be identified just above the pubic ramus. The target is the plane between the 2 structures. While aligning the pubic ramus in the center of the image and targeting the pubic ramus just medial to the AIIS, a 22 Go 10 cm needle will be introduced and 20 ml of anesthetic solution administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam Ketamine arm
Description: Patients in the second group will undergo sedation and analgesic treatment with Ketamine and Midazolam titrated to the best Verbal Rating Score without respiratory and cardiovascular depressant effect.
Study: NCT05876494

Intervention type: DIAGNOSTIC_TEST
Intervention: serum lactate
Description: assessment of serum lactate and mean platelets volume
Study: NCT04874168

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TAP block
Description: bilateral ultrasound-guided TAP block was performed using a 12-4-MHz linear array transducer (ClearVue 350; Philips, Bothell, WA) placed transversely between the iliac crest and costal margin in the anterior axillary line and slid medial-lateral to visualize the external oblique, internal oblique, and trans-versus abdominis muscles; the most lateral (posterior) position obtaining a satisfactory ultrasound image was used

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: bilateral ultrasound-guided TAP block was performed using a 12-4-MHz linear array transducer (ClearVue 350; Philips, Bothell, WA) placed transversely between the iliac crest and costal margin in the anterior axillary line and slid medial-lateral to visualize the external oblique, internal oblique, and trans-versus abdominis muscles; the most lateral (posterior) position obtaining a satisfactory ultrasound image was used

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: bilateral ultrasound-guided TAP block was performed using a 12-4-MHz linear array transducer (ClearVue 350; Philips, Bothell, WA) placed transversely between the iliac crest and costal margin in the anterior axillary line and slid medial-lateral to visualize the external oblique, internal oblique, and trans-versus abdominis muscles; the most lateral (posterior) position obtaining a satisfactory ultrasound image was used
Study: NCT04862208

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maltodextrin supplement
Description: maltodextrin (25g in 12 oz water) 1 hour pre-exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey supplement
Description: whey (25g in 12 oz water) 1 hour pre-exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water
Description: non-caloric control (12 oz flavored water) 1 hour pre-exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Maltodextrin supplement
Description: maltodextrin (25g in 12 oz water) with no exercise
Study: NCT06537128

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LUNA-Adolescent
Description: Learning to Understand and Navigate Anxiety-Adolescent (LUNA-Adolescent) includes parent-led, internet-based cognitive behavioral therapy (CBT) for anxiety among autistic youth.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as Usual includes 12 weekly sessions of transdiagnostic cognitive behavioral therapy (CBT) for anxiety in autistic youth.
Study: NCT06510764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intradermal needles
Description: Disposable intradermal needles will be used for acupoint stimulation and Tai Chong, Taixi, Sanyinjiao, Hegu as well as Yanglingquan are chosen for acupuncture point. Acupuncture point pressure will last for 10 minutes each time, three times per day, and the intradermal needles will be changed every 2 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziyinxiehuo Granules of traditional Chinese Medicine
Description: Ziyinxiehuo Granules of traditional Chinese Medicine which includes shengdi 15g, xuanshen 9g, zexie 9g, zhimu9g, huangbai 9g, zhiguiban 9g, maiya 15g, tiandong 9g, zhigancao 9g,and will be administered after dissolved, 1package every time, 2 times per day after a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziyinxiehuo Granules of traditional Chinese Medicine
Description: Ziyinxiehuo Granules of traditional Chinese Medicine which includes shengdi 15g, xuanshen 9g, zexie 9g, zhimu9g, huangbai 9g, zhiguiban 9g, maiya 15g, tiandong 9g, zhigancao 9g,and will be administered after dissolved, 1package every time, 2 times per day after a meal.
Study: NCT04653246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Via IV at predetermined dosage and predetermined days during each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral, predetermined dosage and predetermined days during each cycle
Study: NCT05959291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuation of Anti-HER-2 Maintenance Treatment
Description: Patients assigned to this group will be asked to discontinue anti-HER-2 maintenance treatment.
Study: NCT04653246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib Injection
Description: SQ Oral, predetermined dosage and predetermined days during each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: IV or Oral predetermined dosage and predetermined days during each cycle
Study: NCT05671835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-101
Description: Orally via a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-101
Description: Orally via a tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally via a tablet.
Study: NCT05771480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive 1500 mg every 3 weeks, or every 4 weeks (in combination with chemotherapy every 3 weeks, or every 2 weeks, respectively) from cycle 1 to cycle 8 of chemotherapy. Upon completion, participants will receive 1500 mg every 4 weeks (as monotherapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine monotherapy
Description: Gemcitabine monotherapy as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine + cisplatin
Description: Gemcitabine plus cisplatin as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab) for WHO/ECOG PS 2 participants only
Study: NCT04987905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: In the study, for 60 minutes once a week for 8 weeks MIND-BE program will be applied to nurses. The program includes formal and informal practices of mindfulness (Getting started, Introduction to MIND-BE, Noticing the autopilot, Power of attention, Simple awareness, Eating awareness, Body awareness, Breath awareness, Sitting awareness, Stress and reactions, Vision awareness, Challenging emotions and situations in business life, Awareness in business life, Awareness and communication, Awareness and compassion, Developing your own practice).
Study: NCT04954820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutathera
Description: 2 additional infusions of Lutathera®
Study: NCT05099445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB000928
Description: INCB000928 200 mg will be administered on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB000928
Description: INCB000928 200 mg will be administered on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB000928
Description: INCB000928 200 mg will be administered on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB000928
Description: INCB000928 200 mg will be administered on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB000928
Description: INCB000928 200 mg will be administered on Day 1 of each treatment period.
Study: NCT04831554

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single chest tube drainage
Description: place single chest tube after surgery of PSP
Study: NCT04991610

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: computed tomography
Description: CT scans will be obtained from patients lying in a supine position using 120 kV tube voltage, 150 effective mA and 1 mm slice thickness parameters.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: computed tomography
Description: CT scans will be obtained from patients lying in a supine position using 120 kV tube voltage, 150 effective mA and 1 mm slice thickness parameters.
Study: NCT06092450

Intervention type: OTHER
Intervention: develop and validate a deep learning radiomics model based on preoperative enhanced CT image
Description: develop and validate a deep learning radiomics model based on preoperative enhanced CT to predict postoperative survival in MIBC
Study: NCT06466707

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of microbiome samples
Description: Collection of skin, oral and vaginal (if applicable) microbiome samples by means of a swab and collection of fecal material using Fecotainer collection kit.
Study: NCT05452785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD-29 (Minocycline) Fasting
Description: In each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD-29 (Minocycline) Fed
Description: In each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast and 30 minutes after the start of a high-fat, high-calorie breakfast.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solodyn (Minocycline) Fasting
Description: In each study period, a single 105 mg dose of SOLODYN® Tablets will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast.
Study: NCT04630834

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Patients will receive both ibuprofen 10mg/kg weight based dosing with a max of 600mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: Patients will receive both ibuprofen 10mg/kg weight based dosing with a max of 600mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: patients will receive acetaminophen 15 mg/kg weight based dosing with a max of 650mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will receive placebo 15mg/kg weight based dosing with a max of 650mg
Study: NCT06401031

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Press Needle
Description: Sham press needle is a surgical adhesive patch without needle, that is placed onto acupuncture point
Study: NCT06463028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serabelisib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Infusion
Study: NCT05562960

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Plasmapheresis
Description: Regular plasmapheresis to remove anti-NRIP autoantibody
Study: NCT05922696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 50.000IU weekly in Group A , or 200.000IU monthly in Group B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 50.000IU weekly in Group A , or 200.000IU monthly in Group B
Study: NCT05679505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular transcutaneous vagus nerve stimulation
Description: Transcutaneous vagus nerve stimulation (taVNS) was performed with an FDA-approved Vagustim stimulation device and an electrode-shaped earpiece. In the participants included in the study and randomized to two groups, i) left ear taVNS was applied to the first group and ii) double-ear taVNS was applied to the second group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular transcutaneous vagus nerve stimulation
Description: Transcutaneous vagus nerve stimulation (taVNS) was performed with an FDA-approved Vagustim stimulation device and an electrode-shaped earpiece. In the participants included in the study and randomized to two groups, i) left ear taVNS was applied to the first group and ii) double-ear taVNS was applied to the second group.
Study: NCT06508021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Dose level A or B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Dose level A or B

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blinded
Study: NCT06388213

Intervention type: DEVICE
Intervention: Gastric Ultrasonography
Description: Evaluation of cross sectional area of the antrum by gastric ultrasonography in healthy patients and in patient treated by GLP-1 receptor agonists after a fasting period (6 hours for solid and 2 hours for clear liquids). For the GLP-1 receptor agonists group the gastric ultrasonochography will be repeated each 2 days during 7 days. In the non GLP-1 receptors agonists group the evaluation will be executed one time.

Intervention type: DEVICE
Intervention: Gastric Ultrasonography
Description: Evaluation of cross sectional area of the antrum by gastric ultrasonography in healthy patients and in patient treated by GLP-1 receptor agonists after a fasting period (6 hours for solid and 2 hours for clear liquids). For the GLP-1 receptor agonists group the gastric ultrasonochography will be repeated each 2 days during 7 days. In the non GLP-1 receptors agonists group the evaluation will be executed one time.
Study: NCT06508021

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Andecaliximab
Description: Dose level A or B (or age adjusted dose)
Study: NCT05521048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Injection [Doxy]
Description: Injections between 0.1 ml to 4 ml of 10mg/ml doxycycline hyclate will be administered to a maximum of three tumors per patient. The dose administered will be calculated based on tumor size, not to exceed the estimated volume of the tumor or a maximum of 4 ml. Injection of 1% lidocaine may be given pre-doxycycline to reduce injection pain.
Study: NCT06474169

Intervention type: OTHER
Intervention: 1 blood sample for each participant
Description: Blood sample for cohort n°1 and n°2 (collection during a peripheral venous blood sample, part of the standard of care for this disease) :~1 blood sample for each patient 28mL of blood (4 tubes, 7mL per tube)~Blood samples for cohort n°3 (collection during blood donation at Etablissement Français du Sang) :~1 blood sample for each healthy donor 14mL of blood (2 tubes, 7mL per tube)
Study: NCT04847921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Description: long-acting lipoglycopeptide antibacterial agent
Study: NCT06372977

Intervention type: DIAGNOSTIC_TEST
Intervention: kappa index
Description: CSF albumin /serum albumin ratio (Qalb) k-index = (CSF kFLC/serum kFLC)/Qalb

Intervention type: DIAGNOSTIC_TEST
Intervention: kappa index
Description: CSF albumin /serum albumin ratio (Qalb) k-index = (CSF kFLC/serum kFLC)/Qalb